While RET-targeting TKIs have provided clinical benefit to patients with MTC, the development of resistant disease can occur and the toxicity of both cabozantinib and vandetanib limit their use in patients with small volume, asymptomatic or indolent disease. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.